Safety of Vasopressor Medications through Peripheral Line in Pediatric Patients in PICU in a Resource-Limited Setting

Table 2

Vasopressor use and peripheral catheter data (n = 369).

Variables
Vasopressor medication used	Dopamine	32 (8.7%)
	Epinephrine	279 (75.6%)
	Norepinephrine	42 (11.4%)
	Milrinone	93 (25.2%)
Maximum dose of vasopressor medication used (µg/kg/min)	Dopamine	15
	Epinephrine	0.25
	Norepinephrine	0.2
	Milrinone	0.8
Median duration of vasopressor medication used (hours) (IQR)		24 (13–48)
Vasopressor inotropic score	<5	147 (39.8%)
	5–10	167 (45.3%)
	11–15	29 (7.9%)
	16–20	20 (5.4%)
	>20	6 (1.6%)
Vasopressor inotropic score (median; IQR)		8 [5–10]
Coadministration of vasopressor medication		77 (20.9%)
Size of peripheral IV catheter	18	20 (5.4%)
	20	69 (18.7%)
	22	101 (27.4%)
	24	179 (48.5%)
Conversion to central venous catheter (CVC)		127 (34.4%)
Reason for CVC conversion	Persistent high inotropic support	30 (8.1%)
	Difficulty to maintain PIV	14 (3.8%)
	Persistent acidosis	32 (8.7%)
	Need for multiple infusions	6 (1.6%)
	Monitoring	13 (3.5%)
	Unknown	30 (8.1%)
Time to CVC; hours (median; IQR)		7 [5–12]
Extravasation		8 (2.2%)

IQR=interquartile range.